Recent advancements in erythrocytes, platelets, and&amp;nbsp;albumin as delivery systems

Xu, Peipei; Wang, Ruju; Wang, Xiaohui; Ouyang, Jian

doi:10.2147/ott.s104691

Cited by 37 publications

(28 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These achievements (summarized in the next sections) are possible only thanks to the exclusive features of these cells which allow them to be engineered without altering their properties or compromising their in vivo circulation. In fact, the biochemical characteristics of RBC, their physiology as well as the molecular mechanisms governing the natural fate of the senescent or damaged cells, make them attractive candidates as carriers of conventional and/or new drugs, as extensively documented in recent, excellent, reviews . RBC are among the most abundant cell types in a human body: they comprise approximately one quarter of the total cell number and are the main component of blood with the crucial role of carriers of oxygen and carbon dioxide.…”

Section: Biology and Circulation Of Human Rbcmentioning

confidence: 99%

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently optimized technologies that permit the reversible opening of nanopores across the red blood cell membrane, give the extraordinary opportunity for reengineering human erythrocytes to be used in different biomedical applications, both for therapeutic and diagnostic purposes. Engineered erythrocytes have been exploited as a system for the controlled release of drugs in circulation upon encapsulation of prodrugs or small molecules; as bioreactors when they are endowed of recombinant enzymes able to catalyze the conversion of toxic metabolite into inert products; as drug targeting system for the delivery of compounds to the reticuloendothelial system inducing proper senescent signals on the drug-loaded erythrocyte membrane; as carrier of contrasting agents for diagnostic procedures. Preclinical development of these different applications has taken advantage from the use of proper animal models whose erythrocytes can be reengineered as the human ones or the encapsulation procedures can be adapted on the basis of their specific erythrocyte biological features. Successful results, obtained both in vitro and in preclinical studies, have prompted several clinicians to start pilot clinical investigations in different conditions and some new companies to start the industrialization of selected loading technologies and to initiate clinical development programs. This short review summarizes the key features that, to the best of our knowledge, have been crucial to advance the products toward regulatory clinical approval making reengineering of erythrocytes a modality to treat patients with limited or absent therapeutic options. WIREs Nanomed Nanobiotechnol 2017, 9:e1454. doi: 10.1002/wnan.1454 For further resources related to this article, please visit the WIREs website.

show abstract

Section: Biology and Circulation Of Human Rbcmentioning

confidence: 99%

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…ix) The ability to maintain approximately ideal zeroorder encapsulated drug release kinetics. Disadvantages [9,14,15] :…”

Section: Introductionmentioning

confidence: 99%

“…The shape of erythrocytes in a normal unshared condition is flexible biconcave discs with a cell diameter of ~7.0 to 10.0 μm and ~2.0 μm thickness [14,16,17] (Figure 1). The biconcave disk shape of the RBCs endowed the highest surface area to volume ratio (SA/V), which facilitates large reversible elastic transformation into any arbitrary shape and enables large deformations, and it is important in order to the maintaining of erythrocyte gas exchange function.…”

Section: Introductionmentioning

confidence: 99%

The terpene-indole alkaloids loaded erythrocytes as a drug carrier: design and assessment

Jeewantha¹,

Сливкин²

2018

Russ Open Med J

View full text Add to dashboard Cite

The aim of this work was to elucidate the certain parameters (morphological, physicochemical) of terpene-indole alkaloids (TIAs) encapsulated human erythrocytes as a drug delivery system, and in addition to providing insight into the functional state of erythrocytes subjected to extracorporeal saturation with TIAs. Methods -A modified hypotonic pre-swelling method was implemented to obtain TIAs encapsulated erythrocytes. The content of entrapped TIAs in the erythrocytes was evaluated by a validated analytical method. The morphological and physicochemical properties of TIAs encapsulated erythrocytes were assessed by turbidity spectrum method and the osmotic resistance (OR) of encapsulated erythrocytes. Also, a series of in vitro tests have been carried out to characterize the drug release, haemoglobin leakage, and stability under storage condition. Results -TIAs loaded erythrocytes with drug encapsulation efficiency -vincristine sulfate (VCR) 42.963 ± 2.648%, and vinblastine sulfate (VLB) 44.266±2.432% were achieved by a modified pre-swelling hypotonic lysis method. Achieving higher TIAs encapsulation efficiency considerably essential in order to deliver a therapeutic success, however using improved encapsulation techniques have been achieved -VCR: 61.071±2.582% and VLB: 62.425±2.5288%, respectively. In the experiments, it was established, the morphological and physicochemical parameters of the obtained TIAs loaded erythrocytes were varied from the control erythrocytes in the order ~20-30%, although loaded erythrocytes can be stored at +4 0 C for 7 days while the encapsulate drug amount without falling below 95.964±0.472%. Conclusion -The stability and functionality of TIAs loaded erythrocytes were demonstrating relatively good performance with comparison to control erythrocytes and can be suggested to conduct in vivo experiment in animals for evaluating therapeutic potential compared to free drug forms.

show abstract

“…Using these methods, platelets could be loaded with therapeutic molecules and directed to the desired tissue (or tumor). The benefits of this type of drug delivery include the ability to deliver molecules to tissues that are traditionally hard to target due to limitations imposed by permeability or retention of the drug, and a reduced need to treat a patient systemically, which often results in unwanted toxicities [69].…”

Section: E Ll C U Lt U R E M E D Iamentioning

confidence: 99%

Scale-up of platelet production from human pluripotent stem cells for developing targeted therapies: advances & challenges

Thon¹,

Karlsson²

2017

Cell Gene Therapy Insights

View full text Add to dashboard Cite

Without question, the future of regenerative medicine is in the scalable production of transfusable human tissues for therapeutic use. Platelets will be among the first of these stem-cell based therapeutic tissues to be developed and adopted for clinical use, most notably because they are anucleate and can be safely irradiated to substantially reduce the risk of teratoma development and other cell contaminants. Furthermore, platelets are short-lived, well characterized, easily transplanted, are not required to be autologous, and support a larger than $20 billion per year global market that relies entirely on human volunteer donors. While we are within a decade of realizing the potential of stem cell-based therapeutics, this was not obvious only several years ago. This article identifies the major logistical challenges associated with commercially scaling platelet production for therapeutic use and our experiential insights into translating this technology to the clinic.

show abstract

Recent advancements in erythrocytes, platelets, and albumin as delivery systems

Cited by 37 publications

References 129 publications

Reengineering red blood cells for cellular therapeutics and diagnostics

Reengineering red blood cells for cellular therapeutics and diagnostics

The terpene-indole alkaloids loaded erythrocytes as a drug carrier: design and assessment

Scale-up of platelet production from human pluripotent stem cells for developing targeted therapies: advances & challenges

Contact Info

Product

Resources

About